Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Consolidated Net Income (2023 - 2025)

Historic Consolidated Net Income for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to -$60.1 million.

  • Immunome's Consolidated Net Income fell 1903.33% to -$60.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$234.2 million, marking a year-over-year increase of 2622.53%. This contributed to the annual value of -$305.8 million for FY2024, which is 17919.29% down from last year.
  • Latest data reveals that Immunome reported Consolidated Net Income of -$60.1 million as of Q3 2025, which was down 1903.33% from -$46.5 million recorded in Q2 2025.
  • In the past 5 years, Immunome's Consolidated Net Income registered a high of -$4.5 million during Q1 2023, and its lowest value of -$132.3 million during Q1 2024.
  • Its 3-year average for Consolidated Net Income is -$51.5 million, with a median of -$46.5 million in 2025.
  • In the last 5 years, Immunome's Consolidated Net Income tumbled by 285904.72% in 2024 and then soared by 6626.13% in 2025.
  • Immunome's Consolidated Net Income (Quarter) stood at -$94.7 million in 2023, then rose by 12.34% to -$83.0 million in 2024, then rose by 27.52% to -$60.1 million in 2025.
  • Its Consolidated Net Income stands at -$60.1 million for Q3 2025, versus -$46.5 million for Q2 2025 and -$44.6 million for Q1 2025.